Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · JERSEY CITY, N.J.-- (BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV).
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · Dermavant has been developing VTAMA cream for the treatment of atopic dermatitis in adults and children 2 years of age and older and released positive topline results from its ADORING 1 and 2 pivotal Phase 3 clinical trials in 1H 2023.
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · Dermavant’s novel product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. Food and Drug ...
Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · JERSEY CITY, N.J.-- (BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, …
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · OGN. VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis....
Organon Completes Acquisition of Dermavant, including …
JERSEY CITY, N.J., October 28, 2024 -- (BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the...
Organon Completes Acquisition of Dermavant, including …
Oct 28, 2024 · Press Release. Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% October 28, 2024 at 9:25 AM EDT. The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.
Organon pays up to $1.2B to acquire Dermavant and its steroid …
Sep 18, 2024 · Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced Wednesday. Under the terms of the deal—which is expected to close in...
Dermavant acquisition expands Organon’s dermatology portfolio
Oct 29, 2024 · Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio. With the deal’s closure, Organon has added Dermavant’s VTAMA (tapinarof) cream 1%, a US Food and Drug Administration (FDA)-approved nonbiologic, non-steroidal topical treatment, to its portfolio.
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to …
Sep 18, 2024 · Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make...